• Retinal Degeneration: Dry AMD is a leading cause of permanent vision loss, traditionally managed only with limited-efficacy nutritional supplements.
  • Mitochondrial Dysfunction: The retina is highly rich in mitochondria. As cells age, mitochondrial efficiency plummets, triggering cell death.
  • Drusen Accumulation: Metabolic waste material (drusen) accumulates beneath the retinal pigment epithelium (RPE), suffocating vital photoreceptors.
  • The Treatment Gap: Historically, no therapeutic options existed to actively restore cellular metabolism or reverse intermediate dry AMD tissue breakdown before advanced atrophy set in.

The Science — What is Photobiomodulation (PBM)?

  • Mechanism of Action: PBM uses precise, low-level light energy to target and stimulate compromised cellular functions rather than generating tissue-damaging heat.
  • Photoacceptor Activation: Light photons are directly absorbed by Cytochrome c Oxidase (CcO), a crucial molecule inside the mitochondrial electron transport chain.
  • Energy Synthesis: Activating CcO drives the proton gradient required to upregulate Adenosine Triphosphate (ATP) production.
  • Secondary Cellular Effects:
    • Enhances local blood flow via local nitric oxide release.
    • Triggers a temporary, safe spike in reactive oxygen species (ROS) to initiate self-repair.
    • Inhibits systemic inflammation and prevents early apoptotic retinal cell death.

The Tool — The Valeda® Light Delivery System

  • FDA Milestone: Authorized by the FDA via the De Novo pathway, making it the first and only non-invasive treatment indicated to improve visual acuity in dry AMD.
  • Multiwavelength Delivery: Simultaneously or sequentially delivers three distinct, clinical-grade wavelengths directly to the retina:
    • 590 nm (Yellow): Stimulates nitric oxide synthesis, maximizing local oxygen and nutrient delivery through vasodilation.
    • 660 nm (Red): Promotes oxygen binding, drives ATP production, and dampens pathways linked to inflammation.
    • 850 nm (Near-Infrared): Enhances deep electron transfer within cell layers to halt photoreceptor breakdown.
  • Delivery Method: Applied painlessly directly through open eyelids (590 nm/850 nm) and closed eyelids (660 nm).

Clinical Application & Protocol

  • Patient Selection: Most effective for patients in the early to intermediate stages of dry AMD with notable drusen deposits before extensive geographic atrophy develops.
  • Treatment Cycle:
    • Intensive initial series: 9 distinct in-office sessions.
    • Compressed timeline: Administered 3 times per week across a 3-week window.
    • Session duration: Fast and painless, requiring less than 5 minutes per treated eye.
  • Maintenance Schedule: The full 9-session treatment cycle is repeated every 4 months to sustain metabolic improvements.

Clinical Trial Data — The LIGHTSITE III Trial

  • Study Design: A rigorous multi-center, double-masked, randomized, sham-controlled trial evaluating 148 eyes over a 24-month period.
  • Primary Metric Baseline: Subjects presented with early-to-intermediate dry AMD and baseline visual acuity across standard letter lines.
  • Key Findings:
    • Met its primary endpoint with statistically significant gains in Best-Corrected Visual Acuity (BCVA).
    • 55% of PBM-treated eyes experienced a significant boost of ≥ 5 letters (1 full line) on an eye chart by Month 13.
    • Placebo (sham) cohorts exhibited no significant improvements or demonstrated steady vision decline.

Visualizing the Outcomes — Vision Gains & Loss Prevention

The table below breaks down the long-term changes in Best-Corrected Visual Acuity (BCVA) observed between the multiwavelength PBM treatment group and the sham control arm at Month 13.

Clinical Metric Observed (Month 13) Valeda® PBM Group Sham Control Group
≥ 5 Letter Gain (~1 Line) 55.0% of eyes (Mean gain: 9.7 letters) 40.8% of eyes
≥ 10 Letter Gain (~2 Lines) 26.4% of eyes (Mean gain: 12.8 letters) 14.9% of eyes
≥ 15 Letter Gain (~3 Lines) 5.5% of eyes 1.9% of eyes
Vision Loss Metrics Significantly fewer eyes lost letters Higher frequency of letter loss (-1 to -15 letters)

Visual Acuity Shift (PBM vs. Sham Control)

The chart below tracks the percentage of eyes experiencing significant vision gains at the primary 13-month trial checkpoint, illustrating Valeda’s therapeutic edge over standard sham groups.

Anatomical Outcomes & Disease Modification

  • Drusen Management: Unlike historic management plans, Valeda achieves true anatomical stabilization or reduction of central drusen volume and thickness.
  • Slowing Progression: PBM substantially lowers the historical rate of progression to late-stage devastating conditions:
    • Delays onset of Geographic Atrophy (GA) (advanced dry AMD tissue death).
    • Reduces conversion rates to exudative (Wet) AMD.
  • Extended Efficacy: Recent long-term extension data indicates that continuous regular maintenance therapy shifts the long-term trajectory of vision loss out to 4.5 years.

Patient Safety & Tolerability Profile

  • Non-Invasive Safety: No injections, structural incisions, or surgical risks involved.
  • Phototoxicity Results: Zero documented cases of phototoxicity across the extensive LIGHTSITE trial programs.
  • Comfort: 100% of trial patients reported completely pain-free treatment sessions without discomfort.
  • Contraindications: Not recommended for patients presenting with extreme clinical photosensitivity or individuals taking light-activated pharmaceuticals.

Conclusion & The Future of AMD Management

  • A New Standard of Care: The Valeda® System shifts intermediate dry AMD care from passive observation via vitamin supplements to active cellular restoration.
  • Proven Efficacy: Clear, verified improvements in central vision, contrast sensitivity, and drusen stabilization.
  • Clinical Integration: Easily deployed within current retinal practices to stop vision loss before permanent cell death takes place.

Valeda™ PBM’s unique mechanism of action works to restore cellular energy production and improve retinal cellular health

The retina is rich in mitochondria, and mitochondrial dysfunction is a known cause of vision loss in dry AMD.

Cytochrome c oxidase (CcO) is a key photoacceptor in the mitochondrial electron transport chain.

Valeda™ PBM wavelengths activate CcO, enhancing electron transport and mitochondrial adenosine triphosphate (ATP) production, the cell’s major source of energy.